{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-010051","form_type":"8-K","ticker":"GILD","cik":"0000882095","company_name":"GILEAD SCIENCES, INC.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:27.124667+00:00","generated_at":"2026-06-06T10:25:54.704731+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Gilead appoints Ted Love, MD, to Board of Directors; board expands to 10","bullets":["Dr. Love elected to Board effective February 1, 2024; board size increased from 9 to 10.","He will serve on Audit Committee beginning after 2024 Annual Meeting, subject to reelection.","Dr. Love is former CEO of Global Blood Therapeutics and current chair of BIO board.","He also serves on boards of Royalty Pharma and Structure Therapeutics.","No arrangement or related-party transactions exist in connection with his appointment."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-010051","json":"https://secwatch.observer/filing/0001104659-24-010051.json","markdown":"https://secwatch.observer/filing/0001104659-24-010051.md","text":"https://secwatch.observer/filing/0001104659-24-010051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/tm244922d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:25:54.704731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"392f14a4bf","claim":"Ted W. Love, M.D. was elected as Director at GILEAD SCIENCES, INC..","evidence_excerpt":"the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/882095/000110465924010051/0001104659-24-010051-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}